Compare Gilead Sciences, Inc. (GILD) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Las Vegas Sands Corp. — how do they compare? Gilead Sciences, Inc. trades at $135.6 (market cap $163.51B), while Las Vegas Sands Corp. trades at $45.76 (market cap $29.68B). The key difference: Gilead Sciences, Inc. is far larger — about 5.5× Las Vegas Sands Corp.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | LVS | |
|---|---|---|
Market Cap | $163.51B | $29.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $69.49 |
52-Week Low | $108.22 | $44.78 |
Enterprise Value | $178.05B | $42.07B |
Dividend Yield | 2.49% | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
LVS trades at $45.40, up 1.38% with strong earnings beats in recent quarters. Technical indicators show bearish momentum despite oversold RSI levels near support at $44. Fundamentally, revenue grew to $13.02B in 2025 with net income of $1.63B, though debt levels remain elevated at 73.15% of assets. Recent news highlights ESG achievements and Macao expansion efforts.
Analyst consensus is bullish with a $65.40 price target (61% buy ratings), but high leverage and bearish technical signals pose near-term risks. Upside depends on sustained gaming recovery and debt management, while macroeconomic pressures could challenge growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
